Simplifying Global Compliance
Patients Advocate Seeks PTO Review of Wyeth’s Tygacil Patent
A patient advocacy group is using a recently created review pathway through the U.S. Patent and Trademark Office to challenge the patent on Wyeth’s antibiotic Tygacil outside a Hatch-Waxman ANDA.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing